Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of LCZ696 in Hepatic Impairment
NCT01621633Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2012
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sacubitril + valsartan in heart failure (HF) (3 arms), sponsored by Novartis. Primary endpoints: Area Under the Plasma Concentration-time Profile From Time Zero to the Time of the Last Quantifiable Concentration at 96 hours, Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time at 96 hours and 1 more. Started Sep 2012; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT01621633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01621633.